×

Indications

Prolia® is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal Read More

Prolia® is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Prolia® reduces the incidence of vertebral, nonvertebral, and hip fractures.

Prolia® is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

Prolia® is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.

Prolia® is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer. In these patients Prolia® also reduced the incidence of vertebral fractures.

Prolia® is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.

Close

Now Approved for 5 Indications

As of May 2018, Prolia® (denosumab) is approved for a new indication.
Click the buttons below to learn more.

For treatment to increase bone mass in men with osteoporosis at high risk for fracture


With 1 dose every 6 months, Prolia® follows your male osteoporosis patients all year long.

  • 60 mg subcutaneous injection in the upper arm, upper thigh, or abdomen by a healthcare professional
  • Pre-existing hypocalcemia must be corrected prior to initiating therapy with Prolia®. Adequately supplement all patients with calcium and vitamin D
  • Multiple vertebral fractures have been reported following Prolia® discontinuation
RISK EVALUATION AND MITIGATION STRATEGY (REMS)

Learn about coverage and multiple fulfillment solutions available for your Prolia® patients.

?

Are your patients losing height?

Learn about height loss as one of the many risk factors to look for when considering your male patients at high risk for osteoporosis-related fracture.

  • This image is for illustration purposes only.
Identifying Patients

Prolia® (denosumab) safety profile.

Learn about the Prolia® Risk Evaluation and Mitigation Strategy Program.

REMS

Learn about Prolia® Important Safety Information.

Important Safety Information
Prolia® is
1 Shot Every
6
Months2

Single-use
prefilled 1 mL syringe

  • 60 mg subcutaneous injection in the upper arm, upper thigh, or abdomen by a healthcare professional
  • Pre-existing hypocalcemia must be corrected prior to initiating therapy with Prolia®. Adequately supplement all patients with calcium and vitamin D
  • Multiple vertebral fractures have been reported following Prolia® discontinuation
  • As a subcutaneous injection, Prolia® does not undergo first-pass metabolism4
  • May lessen patient pill burden
Dosing

Important Safety Information

Following discontinuation of Prolia® treatment, fracture risk increases, including the risk of multiple vertebral fractures. Evaluate an individual’s benefit/risk before initiating treatment with Prolia®. If Prolia® treatment is discontinued, consider transitioning to an alternative antiresorptive therapy.

Prolia® has confirmed medical benefit coverage nationwide.5

You can administer Prolia® in your office or refer your patient to an injection center.

Help your
patients get
Prolia®